SER
Serina Therapeutics, Inc.
+0.09 (+4.17%)2.25USD13.4K成交股數57.2M市值–本益比(近四季)439.6股價營收比-100.0%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 0.00-100% | – | 0.00-100% | 0.00-100% | 130K+2500% | 0.00-100% | 14K-52% | 51K+629% | 5K | 3.1M | 29K | 7K |
| 營業成本 | – | – | – | – | – | – | – | – | – | 1K | 33K | 5K |
| 毛利 | – | – | – | – | – | – | – | – | – | 55K | 34K | 4K |
| 毛利率 | – | – | – | – | – | – | – | – | – | 1.8% | 117.2% | 57.1% |
| 研發費用 | 3.8M | 3.2M | 3.4M | 3.7M | 3.2M | 3.0M | 2.4M | 1.6M | 1.1M | 907K | 603K | 479K |
| 銷售管理費用 | 3.0M | 3.1M | 2.8M | 2.7M | 2.5M | 2.9M | 2.9M | 2.3M | 1.2M | 1.9M | 889K | 473K |
| 營業利益 | −6.8M+22% | – | −6.2M+17% | −6.4M+65% | −5.6M+140% | −5.9M-2531% | −5.3M+263% | −3.9M+309% | −2.3M | 241K | −1.5M | −945K |
| 營業利益率 | – | – | – | – | -4,280.8% | – | -37,942.9% | -7,580.4% | -46,420.0% | 7.8% | -5,044.8% | -13,500.0% |
| 稅後淨利 | −6.4M-1% | −6.9M+43% | −3.3M-337% | −4.6M-188% | −6.4M-57% | −4.8M-558% | 1.4M-20% | 5.2M+544% | −15.0M | 1.1M | 1.8M | 808K |
| 淨利率 | – | – | – | – | -4,960.0% | – | 10,071.4% | 10,203.9% | -300,300.0% | 34.0% | 6,041.4% | 11,542.9% |
| 稀釋 EPS | -0.55-17% | -0.58+18% | -0.31-338% | -0.45-188% | -0.66-88% | -0.49-358% | 0.13-43% | 0.51+364% | -5.38 | 0.19 | 0.23 | 0.11 |
| 稀釋股數 | 16.4M | 12.0M | 10.2M | 10.3M | 10.0M | 9.8M | 10.8M | 10.2M | 2.8M | 7.4M | 7.6M | 7.4K |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 23.0M | 24.5M | 3.1M | 8.6M | 6.0M | 4.3M | 3.2M | 6.1M | 8.7M | 7.6M | 397K | 261K |
| 應收帳款 | – | – | – | – | – | – | – | – | 65K | 57K | 67K | 6K |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 25.8M | 27.3M | 7.0M | 12.4M | 8.9M | 6.7M | 7.4M | 10.7M | 10.9M | 9.0M | 12.2M | 12.3M |
| 有息負債 | – | – | – | – | – | – | 11.2M | – | – | – | – | – |
| 總負債 | 7.1M | 9.7M | 7.0M | 10.8M | 7.3M | 5.2M | 21.3M | 27.1M | 15.2M | 4.9M | 3.9M | 34.6M |
| 股東權益 | 18.7M | 17.6M | −37K | 1.8M | 1.8M | 1.7M | −13.8M | −16.4M | −4.3M | −32.3M | −27.5M | −22.2M |
| 負債比 | 27.4% | 35.4% | 100.5% | 87.2% | 81.6% | 76.8% | 286.0% | 253.1% | 139.7% | 54.2% | 31.9% | 281.6% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | −8.0M | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −4.6M+6% | – | – | – | −4.3M | – | – | −1.6M | – | – | – |
| 資本支出 | – | 25K | – | – | – | 0.00 | – | – | 14K | – | – | – |
| 自由現金流 | – | −4.6M+6% | – | – | – | −4.3M | – | – | −1.6M | – | – | – |
| 折舊攤銷 | – | 0.00 | – | – | – | 0.00 | – | – | 25K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | -31,820.0% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 130K
| Reportable | 130K | 100.0% | +132.1% |
|---|
產品／服務2025 年度 · 130K
| Grant Revenues | 130K | 100.0% | +132.1% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 130K | +132.1% | −19.2M | -14,755.4% | -1.91 | −18.0M |
| FY2024 | 56K | -98.2% | −11.1M | -19,894.6% | -1.51 | −17.2M |
| FY2023 | 3.2M | +9173.5% | 5.3M | 167.1% | 0.73 | −3.0M |
| FY2022 | 34K | -76.4% | −10.5M | -30,770.6% | -9.70 | – |
| FY2021 | 144K | -60.1% | −8.7M | -6,024.3% | -0.23 | – |
| FY2020 | 361K | -79.1% | −10.9M | -3,009.7% | -0.29 | −7.8M |
| FY2019 | 1.7M | +23.8% | −12.2M | -703.4% | -0.33 | −10.8M |
| FY2018 | 1.4M | – | −7.5M | -537.4% | -0.21 | −8.0M |